These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 38764762)

  • 1. Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration.
    Boldys A; Buldak L
    World J Gastroenterol; 2024 May; 30(18):2387-2390. PubMed ID: 38764762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
    Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
    Curr Obes Rep; 2024 Sep; 13(3):510-531. PubMed ID: 38809396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
    Portincasa P; Khalil M; Mahdi L; Perniola V; Idone V; Graziani A; Baffy G; Di Ciaula A
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease?
    Tulone A; Pennisi G; Ciccioli C; Infantino G; La Mantia C; Cannella R; Mercurio F; Petta S
    United European Gastroenterol J; 2024 Jun; 12(5):638-648. PubMed ID: 38659291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intricate interplay between cell metabolism and necroptosis regulation in metabolic dysfunction-associated steatotic liver disease: A narrative review.
    Afonso MB; David JC; Alves MI; Santos AA; Campino G; Ratziu V; Gautheron J; Rodrigues CMP
    Metabolism; 2024 Sep; 158():155975. PubMed ID: 39004396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma.
    Jeong BK; Choi WI; Choi W; Moon J; Lee WH; Choi C; Choi IY; Lee SH; Kim JK; Ju YS; Kim P; Moon YA; Park JY; Kim H
    Nat Commun; 2024 Aug; 15(1):6506. PubMed ID: 39090079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum.
    Vidal-Cevallos P; Sorroza-Martínez AP; Chávez-Tapia NC; Uribe M; Montalvo-Javé EE; Nuño-Lámbarri N
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions.
    Beygi M; Ahi S; Zolghadri S; Stanek A
    Nutrients; 2024 Jul; 16(14):. PubMed ID: 39064665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural history and progression of metabolic dysfunction-associated steatotic liver disease.
    Hagström H; Shang Y; Hegmar H; Nasr P
    Lancet Gastroenterol Hepatol; 2024 Oct; 9(10):944-956. PubMed ID: 39243773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of metabolic dysfunction-associated steatotic liver disease.
    Lekakis V; Papatheodoridis GV
    Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathophysiology of MASLD: an immunometabolic perspective.
    Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
    Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
    Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
    Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics.
    Jiang Y; Wu L; Zhu X; Bian H; Gao X; Xia M
    Lipids Health Dis; 2024 Apr; 23(1):95. PubMed ID: 38566209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
    Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
    Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression.
    Fernández-Tussy P; Cardelo MP; Zhang H; Sun J; Price NL; Boutagy NE; Goedeke L; Cadena-Sandoval M; Xirouchaki CE; Brown W; Yang X; Pastor-Rojo O; Haeusler RA; Bennett AM; Tiganis T; Suárez Y; Fernández-Hernando C
    JCI Insight; 2024 Aug; 9(19):. PubMed ID: 39190492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease.
    Li Y; Qi P; Song SY; Wang Y; Wang H; Cao P; Liu Y; Wang Y
    Biomed Pharmacother; 2024 May; 174():116585. PubMed ID: 38615611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.